Welcome to our dedicated page for Sonoma Pharmaceuticals news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceuticals stock.
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a leader in the healthcare industry, specializing in the development and production of stabilized hypochlorous acid (HOCl) products. Operating globally, the company delivers innovative solutions for wound care, animal health care, eye care, oral care, and dermatological conditions. With products such as Epicyn, Levicyn, Celacyn Gel, SebuDerm, and Ceramax, Sonoma addresses various health concerns including infections, itch, pain, scarring, and inflammation.
The company’s flagship Microcyn® technology is backed by in-vitro and clinical studies, showcasing its antimicrobial, antiviral, and anti-inflammatory properties. Recent achievements include the launch of LumacynTM Clarifying Mist for over-the-counter use in the U.S., and an agreement with NovaBay Pharmaceuticals for the sale of Avenova®-branded products in the EU.
Sonoma Pharmaceuticals has its headquarters in Boulder, Colorado, with additional manufacturing operations in Guadalajara, Mexico, and European marketing and sales offices in Roermond, Netherlands. The company's products are available in 55 countries, either directly or through partners, and it continues to seek new distribution opportunities.
Financially, Sonoma reported a 7% increase in quarterly revenues to $3.2 million for the period ending December 31, 2023. U.S. sales saw a 14% increase, supported by strong demand for consumer-focused animal health care and wound care products. The company’s strategic investments in R&D and expansion of distributor networks have started to yield results, reflected in improved margins and reduced operating expenses.
For more information, visit the official website at www.sonomapharma.com or contact their customer service at 720-452-9690 or customerservice@sonomapharma.com.
Sonoma Pharmaceuticals (SNOA) reported a mixed financial performance for Q2 and six months ended September 30, 2022. Revenues for Q2 were $3.3 million, a decrease of 11% from $3.7 million year-over-year, while international sales grew by 18%. Gross profit improved to 40% from 33% due to increased production efficiency. Operating loss decreased by 24%, reaching $0.9 million. The total net loss before taxes for six months was $1.9 million, up from $1.2 million last year. The company is optimistic about future profitability driven by a successful transition to a distribution model.
Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the launch of two dermatological products: Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn Advanced Skin Repair Cooling Mist for over-the-counter use in the U.S. Reliefacyn targets symptoms of eczema and skin irritations, while Rejuvacyn aids recovery after cosmetic procedures. Both products emphasize natural formulation and efficacy in healing. CEO Amy Trombly highlighted the expansion of their consumer-focused product line to address common skin conditions. Products are available via the company’s website and distributors.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation at the CPHI Conference in Frankfurt, Germany, from November 1-3, 2022. The company aims to expand its market presence in the European Union by seeking new partners for its dermatology products, including treatments for acne, atopic dermatitis, and scar management. Sonoma's products, known for their safety and effectiveness, leverage Microcyn® Technology to improve quality of life globally. CEO Amy Trombly emphasized the focus on establishing connections with pharmaceutical leaders to grow their European business.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 73% revenue increase from Q4 2022 and 8% from Q1 2022, with total revenues of $4.0 million for the quarter ended June 30, 2022. The company also reduced net loss by 19% to $0.9 million and saw a 44% decline in net loss per share. While gross profit margins lowered to 36%, Sonoma's focus on commercialization and expanding partnerships is expected to enhance future growth. The firm launched new products and expanded its distributor network, indicating robust international performance despite a drop in U.S. sales.
Sonoma Pharmaceuticals (Nasdaq:SNOA) has launched the MicrocynVS line of products specifically for veterinarians, aimed at addressing various animal health issues including wounds and infections. The products leverage patented Microcyn technology containing stabilized hypochlorous acid, enhancing healing processes in animals. A non-exclusive distribution agreement with DV Medical Supply has been established to roll out these products to over 700 veterinary offices across the U.S. MicrocynVS is expected to significantly improve veterinary care and reduce inventory costs for veterinarians.
Sonoma Pharmaceuticals (SNOA) reported Q4 2022 revenues of $2.3 million, a 7% increase from $2.2 million in Q4 2021. The net loss per share improved to $2.9 million, down 14% year-over-year. Operating expenses rose 20% to $3.2 million, primarily due to reconciliations related to the Rx dermatology divestiture. For the fiscal year, total revenue fell to $12.6 million, a $6 million decrease from $18.6 million in FY 2021. Cash reserves stand at $7.4 million, reflecting a strong balance sheet amid transitions toward profitability and growth.
Sonoma Pharmaceuticals (SNOA) announced that its Nanocyn hospital-grade disinfectant has been added to the U.S. Environmental Protection Agency’s List N, which includes COVID-19 disinfectants. This inclusion signifies extended approval for Nanocyn, which was initially approved for use as a disinfectant in April 2022. Additionally, Nanocyn achieved European Standard (EN) 17272 for Airborne Room Disinfection, enhancing its application in healthcare settings. The product has a short contact time of 30 seconds to eliminate viruses and is categorized as low toxicity by the EPA.
Sonoma Pharmaceuticals, Inc. (SNOA) announces EPA approval for Nanocyn®, a hospital-grade disinfectant developed with MicroSafe Group. Utilizing patented Microcyn® technology, Nanocyn® effectively reduces infection risk on hard surfaces, killing various bacteria and viruses, including norovirus, in just 30 seconds. The product, already distributed in Europe, the Middle East, and Australia, now has the potential to enter the U.S. market. With a low toxicity profile and no special handling requirements, Nanocyn® aims to enhance infection control in high-risk environments.
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) has launched Microdox®, a new urinary tract infection catheter and bladder rinse, in New Zealand, Australia, and South Africa. This innovative product utilizes Sonoma's patented Microcyn® Technology and is designed to treat and prevent urinary tract infections (UTIs) by effectively removing UTI-causing bacteria and biofilms. The solution is non-irritating and non-toxic, ready for immediate use through partners like Te Arai BioFarma and NuAngle. The company aims to improve patient quality of life and tackle antibiotic-resistant infections.
Sonoma Pharmaceuticals (SNOA) reported a 41% decline in revenue for Q3 2021, totaling $2.9 million, due to the termination of its low-margin contract with Invekra. Despite this, gross profit improved to 41% of revenues, up 1% year-over-year and 8% sequentially. The company reported a net loss of $(944,000) compared to $(626,000) in the prior year. Total operating expenses rose slightly by 1%. Cash reserves increased to $8.5 million, indicating a strengthened balance sheet.
FAQ
What is the current stock price of Sonoma Pharmaceuticals (SNOA)?
What is the market cap of Sonoma Pharmaceuticals (SNOA)?
What does Sonoma Pharmaceuticals specialize in?
What are some key products of Sonoma Pharmaceuticals?
Where is Sonoma Pharmaceuticals headquartered?
How did Sonoma Pharmaceuticals perform financially in the latest quarter?
What recent product launches has Sonoma Pharmaceuticals announced?
Who are some of Sonoma Pharmaceuticals' partners?
In how many countries are Sonoma Pharmaceuticals' products available?
What technology is central to Sonoma Pharmaceuticals' product line?
Where can consumers purchase Sonoma Pharmaceuticals' products?
How can I contact Sonoma Pharmaceuticals for partnership opportunities?
